Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective analysis study of a single-center experience of unselected autologous tumor infiltrating lymphocyte for treatment of advanced cutaneous melanoma

Next Previous
X
Search
Trial Profile

A retrospective analysis study of a single-center experience of unselected autologous tumor infiltrating lymphocyte for treatment of advanced cutaneous melanoma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ITIL-168 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Malignant melanoma; Skin cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 26 May 2021 New trial record
    • 10 Apr 2021 Results (Data cutoff 31 Dec 2019) assessing efficacy and safety of unselected autologous tumor infiltrating lymphocyte therapy in advanced cutaneous melanoma patients, presented at the 112th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top